Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins

Journal of Molecular Biology

Volumn 267, Issue 3, 1997, Pages 561-569

  McCarthy, Barry J ^a   Worrall, D Margaret ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Chimeric fusion proteins; Hinge region; Ovalbumin; Plasminogen activator inhibitor 2; Serpin

Indexed keywords

HYBRID PROTEIN; MUTANT PROTEIN; OVALBUMIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UROKINASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

EID: 0031552379     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1996.0909     Document Type: Article

References (39)

1. Antalis T. M., Clark M. A., Barnes T., Lehrbach P. R., Devine P. L., Schevzov G., Goss N. H., Stephens R. W., Tolstoshev P. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc. Natl Acad. Sci., USA. 85:1988;985-989.
2. Barnes R. C., Worrall D. M. Identification of a novel human serpin gene; cloning sequencing and expression of leupin. FEBS Letters. 373:1995;61-65.
3. Baumann U., Bode W., Huber R., Travis J., Potempa J. Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95 A resolution. J. Mol. Biol. 226:1992;1207-1218.
4. Berkenpas M. B., Lawrence D. A., Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14:1995;2969-2977.
5. Carrell R. W., Stein P. E. The biostructural pathology of the serpins : critical function of sheet opening mechanism. Biol. Chem. Hoppe-Seyler. 377:1996;1-17.
6. Creighton T. E. Electrophoretic analysis of the unfolding of proteins by urea. J. Mol. Biol. 129:1979;235-264.
7. Engh R. A., Wright H. T., Huber R. Modeling the intact form of the alpha 1-proteinase inhibitor. Protein Eng. 3:1990;469-477.
8. Gettins P. Absence of large-scale conformational change upon limited proteolysis of ovalbumin, the prototypic serpin. J. Biol. Chem. 264:1989;3781-3785.
9. Ho S. N., Hunt H. D., Horton R. M., Pullen J. K., Pease L. R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
10. 14residue on substrate and inhibitory pathways. Biochemistry. 33:1994;8538-8547.
11. Hopkins P. C., Carrell R. W., Stone S. R. Effects of mutations in the hinge region of serpins. Biochemistry. 32:1993;7650-7657.
12. Hopkins P. C. R., Whisstock J. Function of maspin. Science. 265:1994;1893-1894.
13. Huber R., Carrell R. W. Implications of the three-dimensional structure of a1-antitrypsin for structure and function of serpins. Biochemistry. 28:1989;8951-8966.
14. Hunt L. T., Dayhoff M. O. A surprising new protein superfamily containing ovalbumin, antithrombin lll and a1-proteinase inhibitor. Biochem. Biophys. Res. Commun. 95:1980;864-871.
15. Huntington J. A., Patston P. A., Gettins P. G. S-ovalbumin, an ovalbumin conformer with properties analogous to those of loop-inserted serpins. Protein Sci. 4:1995;613-621.
16. Lawrence D. A., Olson S. T., Palaniappan S., Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry. 33:1994;3643-3648.
17. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177:1984;531-557.
18. Mast A. E., Enghild J. J., Pizzo S. V., Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry. 30:1991;1723-1730.
19. McReynolds L., O'Malley B. W., Nisbet A. D., Fothergill J. E., Givol D., Fields S., Robertson M., Brownlee G. G. Sequence of chicken ovalbumin mRNA. Nature. 273:1978;723-728.
20. Mercereau-Puijalon O., Royal A., Cami B., Garapin A., Krust A., Gannon F., Kourilsky P. Synthesis of an ovalbumin-like protein by Escherichia coli K12 harbouring a recombinant plasmid. Nature. 275:1978;505-510.
21. Mikus P., Urano T., Liljestrom P., Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur. J. Biochem. 218:1993;1071-1082.
22. Pemberton P. A., Stein P. E., Pepys M. B., Potter J. M., Carrell R. W. Hormone binding globulins undergo serpin conformational change in inflammation. Nature. 336:1988;257-258.
23. Pemberton P. A., Wong D. T., Gibson H. L., Kiefer M. C., Fitzpatrick P. A., Sager R., Barr P. J. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J. Biol. Chem. 270:1995;15832-15837.
24. Pickup D. J., Ink B. S., Hu W., Ray C. A., Joklik W. K. Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. Proc. Natl Acad. Sci. USA. 83:1986;7698-7702.
25. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269:1994;15957-15960.
26. Remold-O' Donnell E. The ovalbumin family of serpin proteins. FEBS Letters. 315:1993;105-108.
27. Schulze A. J., Huber R., Bode W., Engh R. A. Structural aspects of serpin inhibition. FEBS Letters. 344:1994;117-124.
28. Sheffield W. P., Blajchman M. A. Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin. FEBS Letters. 365:1995;189-192.
29. Stein P. E., Carrell R. W. What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct. Biol. 2:1995;96-113.
30. Stein P., Chothia C. Serpin tertiary structure transformation. J. Mol. Biol. 221:1991;615-621.
31. Stein P. E., Tewkesbury D. A., Carrell R. W. Ovalbumin and angiotensinogen lack serpin S-R conformational change. Biochem. J. 262:1989;103-107.
32. Stein P. E., Leslie A. G., Finch J. T., Turnell W. G., McLaughlin P. J., Carrell R. W. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature. 347:1990;99-102.
33. Stein P. E., Leslie A. G., Finch J. T., Carrell R. W. Crystal structure of uncleaved ovalbumin at 1.95 A resolution. J. Mol. Biol. 221:1991;941-959.
34. Suminami Y., Kishi F., Sekiguchi K., Kato H. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem. Biophys. Res. Commun. 181:1991;51-58.
35. Takahashi N., Koseki T., Doi E., Hirose M. Role of intrachain disulfide bond in the conformation and stability of ovalbumin. J. Biochem. (Tokyo). 109:1991;846-851.
36. Wei A., Rubin H., Cooperman B. S., Christianson D. W. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct. Biol. 1:1994;251-258.
37. Wright H. T., Scarsdale J. N. Structural basis for serpin inhibitory activity. Proteins: Struct. Funct. Genet. 22:1995;210-225.
38. Wright H. T., Qian H. X., Huber R. Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor. J. Mol. Biol. 213:1990;513-528.
39. Zou Z., Anisowicz A., Hendrix M. J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:1994;526-529.